Navigation Links
PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:5/16/2013

SOUTH PLAINFIELD, N.J., May 16, 2013 /PRNewswire/ -- PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.

(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, or Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 1-800-221-1037; email: newyork.prospectus@credit-suisse.com.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and potential commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
2. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
4. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
5. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
6. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
7. Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
8. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
9. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
10. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
11. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... , May 19, 2016 ... World Congestive Heart Failure (CHF) Treatment Devices Market - ... CHF treatment devices market would reach $14.8 billion by ... 2022. Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate ... period. North America is projected ...
(Date:5/19/2016)... 19, 2016 Research ... "Global In-Vitro Diagnostics (IVD) Market Size, Market ... Key Players, Competitive Strategies and Forecasts, 2012 ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... research report forecasts on In-Vitro Diagnostics (IVD) ...
(Date:5/19/2016)...  IBM,s (NYSE:   IBM )  World Community Grid ... drug candidates to cure Zika, a fast spreading virus ... public health emergency. IBM and a global ... or Android device to join the #OpenZika project. Volunteers ... help; they simply  run an app   on ...
Breaking Medicine Technology:
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... Researchers ... is so routine. A fresh look at this technique may yield big benefits. ... reproducibility of experiments in a cell culture laboratory—and lessen the risk of ...
(Date:5/23/2016)... New York, NY (PRWEB) , ... May 23, 2016 , ... ... revolutionary, sport-injury preventative testing program for athletes. This is the first time this type ... South California, is being made available to the public in New York. , With ...
(Date:5/23/2016)... ... 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance advisory network ... September 15 and 16, 2016 in San Diego, CA. The two day summit ... be one of the largest gatherings of medical device companies, suppliers, professionals and experts ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... 23, 2016 , ... Hadley Institute for the Blind and ... blind or visually impaired, announces the election of Julie S. Tye as its ... Board of Trustees retained Morris & Berger, a firm specializing in non-profit executive ...
Breaking Medicine News(10 mins):